Barter - Figure 27 - REVEAL HPS3-TIMI55 Text

The CETP inhibitor that is currently being assessed for benefit in statin treated patients with residual risk is anacetrapib. The prospective trial, the Randomized Evaluation of the Effects of Anacetrapib through Lipid modification (REVEAL HPS3-TIMI55) trial, is being conducted in North America, Europe, and Asia. The first patients are currently being enrolled, with a total planned enrollment of 30,000 patients with CVD, all on background therapy of LDL cholesterol lowering with atorvastatin. Patients will be randomized to receive anacetrapib 100 mg/day versus placebo, with a scheduled follow- up of 4 years, but it is an event driven trial and completion will be when a sufficient number of the pre-specified outcomes has occurred. The primary outcome is a composite of coronary death, MI, or coronary revascularization.

In summary, the status of CETP inhibition at this time is that we do not know yet whether to expect that the result will be positive, but there is definitely insufficient cause, based on the evidence to date, to expect them to be negative.

Barter P. J Clin Lipidol. 2011; 5(6).